I am newbie here but I think the difference between Pharmaxis and Syntara as companies have to been taken in context and not discuss the MC and SP in isolation.
PXS had a $14 Mn per year drain on the cash while SNT is much leaner, has funded trials, with cash in the bank and more R&D refunds on the way. SNT now is focused on clinical trials and not trying to run a manufacturing plant and managing 75 people. To top that we have 4 clinical trials and 3 papers in Nature, funding from Parkinson’s UK etc., providing external validation.
While in this transformation from caterpillar to butterfly is seen by SHs, outsiders with little knowledge only see a company whose SP has languished for a year, board change. Renaming the company also probably hasn’t helped as people may not follow the new code.
We SHs see all positives from inside-out view and outside-in view probably needs education and change which I think the CEO is working on with multiple stakeholders presentations.
AIMO. No advice.
- Forums
- ASX - By Stock
- SNT
- SNT - General Discussions
SNT - General Discussions, page-88
-
- There are more pages in this discussion • 30 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SNT (ASX) to my watchlist
(20min delay)
|
|||||
Last
3.9¢ |
Change
0.003(8.33%) |
Mkt cap ! $53.54M |
Open | High | Low | Value | Volume |
3.7¢ | 4.0¢ | 3.7¢ | $80.41K | 2.085M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 152202 | 3.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.0¢ | 25989 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 152202 | 0.039 |
2 | 831600 | 0.038 |
2 | 680000 | 0.037 |
4 | 503284 | 0.036 |
7 | 1339204 | 0.035 |
Price($) | Vol. | No. |
---|---|---|
0.040 | 15726 | 1 |
0.042 | 300000 | 1 |
0.043 | 200000 | 1 |
0.044 | 358500 | 1 |
0.045 | 1900 | 1 |
Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |